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Abstract
Background and aims: Charcot-Marie-Tooth (CMT) is a common sensory-motor polyneuropathy with a prevalence of 1/2500. It is divided 
into different subgroups and has various hereditary patterns. Among the different subgroups of CMT, type 1A is the most prevalent form 
of the disease, which is created due to the duplication of the PMP22 gene. In patients has a deletion in the PMP22 gene, the hereditary 
neuropathic disease is known to be liable to pressure. The aim of this study was to identify the patients affected by the disease with the new, 
simple, and fast qPCR method and to investigate the appropriateness of this method in evaluating these types of mutations.
Methods: In this analytical-descriptive study (code:IR.SKUMS.REC.1394.152), gene duplication and deletion in the patients were studied 
using the Excel software. The blood samples of 15 families afflicted with CMT and 49 healthy individuals were collected in EDTA 
anticoagulant tubes and analyzed. DNA extraction and quantitative real-time PCR method were applied for the PMP22 gene as the target 
gene and the albumin gene as the internal control gene.
Results: Two genes were compared in each patient, and it was found that 46% of the subjects had duplication in the PMP22 gene.
Conclusion: The qPCR method is an easy and fast way to detect gene duplication and deletion in CMT patients. It does not require any 
statistical software and can be performed without needing for parental DNA. In addition, the results of this study are consistent with the 
results of various studies in some countries of the world where the highest levels of deletion and duplication in PMP22 gene are seen.
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Introduction 
The Charcot-Marie-Tooth (CMT), HNPP (hereditary 
neuropathy with liability to pressure palsy), and Dejerine-
Sottas are among the sensory-motor polyneuropathies 
that are genetically and clinically heterogeneous. CMT, 
with a prevalence of 1 in 2500, is the most common 
type of neuropathy with a genetic cause (1, 2). Some 
forms of CMT are inherited in an autosomal dominant 
manner; however, some other forms are inherited in an 
autosomal recessive manner. Based on the progression 
of the disease, it can be categorized into 2 types: CMT1 
(the demyelinating form) and CMT2 (the axonal form). 
According to electrophysiological criteria, it can be stated 
that CMT1 has a nerve conduction velocity of less than 
38 m/s, and demyelination and remyelination symptoms 
are seen in the biopsy of the sural nerve. In CMT2, the 
nerve conduction velocity is normal or slightly reduced 
(3). Many genes and loci have been identified for each 
subgroup. In demyelinating CMT with the dominant 
autosomal hereditary, the cause of the disease in many 
cases is the PMP22 gene duplication at locus 17p11.2, 
which leads to CMT1A disease, but mutations in other 
genes can also be the cause of this subtype, including the 
MPZ gene at locus 1 q22, the EGR2 gene at locus 10 
q21, and the LITAF gene at locus 16 p13 (4). CMT1A 
is the most common form of CMT disease with a 
prevalence of 1/3300. About 70% of CMT1A cases are 
associated with 1.5-Mb duplication at locus 17p11.2-
12, where the peripheral myelin protein (PMP22) gene 
is located (5, 6). Molecular methods have been widely 
used to study the structure and function of genes (7-15). 
To investigate deletions and duplications of the PMP22 
gene, various methods such as Southern blotting, FISH, 
PFGF, STR-PCR, and the quantitative PCR can be used 
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through SYBR Green I or TaqMan methods. Since STR-
PCR analysis is fast and cost-effective, it is widely used, 
but low sensitivity is considered a disadvantage thereof. 
Quantitative PCR methods are fast in case TaqMan is used, 
and also are proprietary because of the use of the probes. 
The SYBR Green PCR method can be used to investigate 
various deletions and duplications in different organisms 
(16). The aim of this study was to determine the frequency 
of PMP22 gene deletion and duplication mutations using 
real-time PCR method in patients with CMT1A and to 
examine the appropriateness of this method for studying 
these types of mutations.
Materials and Methods
Patients
Peripheral blood samples were collected in EDTA 
anticoagulant tubes from 15 families (49 individuals) 
including 5 children, 13 women, and 31 men, out of 
whom one was affected by the disease. Moreover, 49 
healthy volunteers, out of whom no one was affected 
by neuropathy, were sampled as normal controls. The 
criteria for entering the study were evaluating the speed of 
conduction of the nerve and muscle by the specialist and 
giving the demyelinating CMT report.
DNA extraction
DNA extraction of the collected samples was performed. 
DNA was extracted from EDTA anticoagulant blood 
samples using the recommended method by DNA 
extraction kit (Cinnagen, Iran). The quality and quantity 
of the extracted DNA were examined using the agarose 
gel and spectrophotometer (Nanodrop 2000 Thermo 
Scientific).
Real-time PCR
Exon 4 was considered as the target sequence for the 
PMP22 gene, and Exon 12 was selected as the reference 
sequence for the albumin gene. The sequence of the 
primers designed in this study was obtained from a similar 
article (17), and after being reviewed in the Vector NTI 
software for the formation of a hair pin and primer dimer, 
as well as the correctness of primers for the desired genes, 
the sequence was ordered to be synthesized by the Korean 
Macrogene Company (Table 1) (17).
At the beginning of the experiment, different 
concentrations of DNA were prepared with a factor of 1 to 
5. The real-time PCR was performed on the albumin gene 
at concentrations of 120, 24, 8.4, 0.96, and 0.19 ng for a 
healthy control sample and repeated three times. For each 
reaction, 5 μL of cyber green, 3 μL of water (Fermentas), 
and forward and reverse primers (made by Macrogene 
Company) were added to the final concentration of 
1 pM. Then, 9 μL of Master Mix and different DNA 
concentrations were added to each microtube. Thereafter, 
the Rotor-Gene Q device (Qiagen) was used to amplify 
the intended parts to be assured of the specificity of the 
primers, the optimization of DNA concentration, as well 
as the efficiency of the primers.
The real-time PCR program was performed according 
to the SYBR Green protocol as follows: Initial activation at 
95°C for 10 minutes, with 40 cycles including unwrapping 
at 95°C for 15 seconds, connecting the primers at 60°C 
for 20 seconds, and expanding at 72°C for 25 seconds. 
The temperature was kept in the range of 72 to 95°C to 
form the melting curve. For final confirmation, the PCR 
products were placed on the 8% polyacrylamide gel to 
determine the accuracy of the amplified parts (Figure 1). 
Analysis of real-time PCR data using ΔΔCT
To use this method, 4 CTs (cycle of threshold) are needed. 
The CTs of the desired gene in the control (healthy) and 
under study (patient) samples and CTs of the internal 
control gene in the control and under study samples were 
Figure 1. The Specificity of the Primers in Healthy Samples.
M: Marker of 100 bp DNA ladder, Alb: The albumin gene amplified 
by the real-time PCR method in a healthy person, PMP22: Peripheral 
myelin protein gene amplified in a healthy person.
Table 1. The designed primers specifications for PMP22 and albumin genes
Gene Primer sequence Primer Length of the amplified part TM Primer length
Albumin (Exon12)
TGTTGCATGAGAAAACGCCA Forward
72 bp
55 20
GTCGCCTGTTCACCAAGGAT Reverse 53.8 20
PMP22 (Exon4)
TCTGTCCAGGCCACCATGA Forward
84 bp
54.3 19
GAAGAGTTGGCAGAAGAACAGGA Reverse 54.3 23
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examined. Then, according to the Livak formula, data 
analysis was performed, and finally the obtained results 
were examined compared with the control population 
and the internal control gene (17). For each patient, two 
target and internal control genes were compared and Ct 
difference was calculated. Afterwards, the difference in 
the healthy control population was also calculated. The 
difference between these two CTs was placed in the Livak 
Formula (2-ΔΔCt), and the resulting values being about 1.5 
were identified as individuals with duplication.
 △△Ct=[Ct albumin-Ct PMP22 (control sample)]-[Ct 
albumin-Ct PMP22 (unknown sample)]
Results
The real-time PCR was performed and the products were 
placed on the 8% polyacrylamide gel to examine the 
specificity of the primers, which is shown in Figure 1.
The graphs of amplification of this gene in healthy and 
patient samples are presented in Figure 2, as follows:
The graphs of both genes in the healthy person are almost 
in agreement, and Cts are almost identical in both genes, 
while the Cts obtained from a patient with PMP22 gene 
duplication are smaller.
The real-time PCR was conducted, and the results were 
transferred to Excel software. Then, the calculations were 
performed using the Livak formula. In control subjects, the 
mean values of CT for the albumin and PMP22 genes were 
22.91 and 22.97, respectively. In the following, these values 
were calculated separately for all patients using the formula 
2-ΔΔCt, and the results were interpreted. It was revealed that 
46% of the studied population had a duplication in the 
PMP22 gene.
The results of real-time PCR are presented in Table 
2, showing that individuals number 1, 2, 4, and 6 have 
duplication in the PMP22 gene.
Discussion
CMT is a common neurological disorder that occurs due 
to different mutations in different genes. PMP22 and 
MPZ are the two genes with higher mutation rates found 
in various gene communities. PMP22 and MPZ genes 
have been studied as two very important genes involved 
in diseases in many countries around the world, such as 
the United States, Finland, France, Korea, Russia, Spain, 
Sweden, and Japan, to identify the patients with CMT 
using various methods. The number of families varies from 
11 to 227 and the frequency of duplication in the PMP22 
gene has been the highest in all studies. As noted, extensive 
studies have been conducted around the world on the CMT 
disease, including the study of chromosomal rearrangement 
in the 17p11.2 region. In Ukrainian patients, several cases 
of duplication in this region without a family history of 
disease were found, with the greatest cause reported to 
be duplication in the PMP22 gene, which accounted for 
95% of the cases (18). In another study, 119 families from 
Slovakia with CMT were examined, out of whom 40 had 
gene duplication and 7 had gene deletion (19). In a large 
study in the United States of America, 95% of the positive 
results belonged to four genes: PMP22, MPZ, MFN2, 
and GJB1. Therefore, it was concluded that it would be 
better to examine these four genes first in the patients (20). 
In general, in most countries where this disease has been 
studied, the frequencies of various mutations in the PMP22 
gene, including the duplication and deletion, have ranked 
the highest number, except for Japan where the mutation 
in the PMP22 gene did not have the highest frequency 
due to the founder effect. In this study, the PMP22 gene 
duplication and deletion on the short arm of chromosome 
17 were investigated using the qPCR method and it was 
found that 46% of patients had duplication in the PMP22 
gene. Thanks to the ease, fastness, and also lack of need for 
parental DNA, qPCR is a cost-effective method used in 
this study, while other methods such as Southern Blotting, 
STR-PCR, and MLPA have been applied in other earlier 
studies. It has been shown in this study that the PMP22 
gene duplication is the most common cause of CMT1A.
Conclusion
Considering the prevalence (1/2500) of CMT disease, 
qPCR was used as a quick, easy, and cost-effective method 
in this study, which can replace old diagnostic methods. 
The prevalence of duplication of this gene among the other 
genes involved in the development of CMT is of the highest 
rate and considered the main cause of this disease. In the 
Table 2. The results of real-time PCR for both internal control and target 
genes.
CT PMP22 CT Alb
CT Alb-
PMP22(Con)
CT Alb-
PMP22(Sam)
ΔΔCT 2-ΔΔCT
21.82 22.41 -0.06 0.59 -0.65 1.56
22.31 22.88 -0.06 0.57 -0.63 1.54
23.59 23.69 -0.06 0.1 -0.16 1.11
22 22.64 -0.06 0.64 -0.70 1.63
21.44 21.42 -0.06 -0.02 -0.04 1.02
21.07 21.7 -0.06 0.63 -0.69 1.61
21.28 21.39 -0.06 0.11 -0.17 1.12
21.44 21.38 -0.06 -0.06 0 1
Figure 2. The Amplification Plot of Alb and PMP22 genes obtained from a healthy person 
and a person with the PMP22 gene duplication.
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study conducted on 15 affected families in Chaharmahal 
and Bakhtiari and Isfahan provinces, 46% of patients were 
diagnosed with CMT1A.It seems that duplication of the 
PMP22 gene has the highest rate of prevalence among 
the causes of the disease in these two provinces like most 
countries in the world.
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